Our technology can be used for chronic disease management, triage, or hospital-at-home use cases in adults.
We’ve spent many years on research, R&D, and clinical validation so that you don’t need to.
Your app now generates unique and objective insights that patients cannot obtain anywhere else.
You stay in full control of any generated data. Our CE certification protects users and allows you to make medical claims.
Zurich, Switzerland, January 19th, 2021 – Recently incorporated digital biomarker startup Resmonics has received financial support from the CSS insurance in its pre-seed financing round. The due diligence was conducted by Redstone on behalf of CSS Insurance. The funding will be used to accelerate the development of its first product, a smartphone-based digital biomarker service for patients suffering from asthma or COPD, and to certify it as a medical device. ...
The jury of Venture Leaders Mobile 2021 selected 10 start-ups. They represent a range of sectors from digital health to insurtech and advance innovations in artificial intelligence, big data, or blockchain. The selected teams will travel to Barcelona to attend the Mobile World Congress from June 28–July 1, 2021, planned as an in-person event with hybrid experiences.
Resmonics wins Venture Kick's final stage of financial and entrepreneurial support. Their first product, ResGuard Med, is a CE-certified early-warning system that helps patients with chronic respiratory diseases manage their condition.
We congratulate the Digital Health Lab Day 2021 Startup pitching winner in the category "Jury Voting": Resmonics. The startup prevailed over the 8 other finalists on the basis of 5 evaluation dimensions.
In collaboration with Finish KAMU Health and Swiss CSS insurance, ETH spinoff Resmonics has launched its first product ResGuard Med. The CE-certified solution gives patients with chronic and acute respiratory symptoms unique insights into their disease.
Senior Full Stack Developer
Senior Data Scientist